| Circulating biomarkers of glycemia in diabetes management and implications for personalized medicine. | |
| | |
MedLine Citation:
|
PMID: 20144323 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Personalized medicine represents a new model in how the medical community approaches disease management. Rather than managing those with a particular diagnosis according to an established guideline, the personalized medicine model seeks to identify unique characteristics within each patient that can serve as a basis for disease characterization and specialized treatment. This article reviews several circulating biomarkers of glycemia that are used in the medical management of diabetes, to include hemoglobin A1c, fructosamine, and 1,5-anhydroglucitol. Within the discussion, specific attention is paid to areas in which biomarker results do not correlate with anticipated results based on actual mean glycemia. Variability between actual and anticipated results of the various biomarker tests represents opportunities to identify previously undefined subcategories of diabetes and groups of patients that fit into these subcategories. Finally, research areas are proposed for these subcategories that would further promote the field of personalized medicine in diabetes. |
| | |
Authors:
|
Mark W True |
Related Documents
:
|
22556843 - Ayurvedic rationale of the southern indian vegetable soup saaru or rasam. 17062393 - Dds for anti-aging and regenerative medicine (review). 20540483 - Office-based strategies for the management of obesity. |
Publication Detail:
|
Type: Journal Article; Review Date: 2009-07-01 |
Journal Detail:
|
Title: Journal of diabetes science and technology Volume: 3 ISSN: 1932-2968 ISO Abbreviation: J Diabetes Sci Technol Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2010-02-10 Completed Date: 2010-06-02 Revised Date: 2011-03-11 |
Medline Journal Info:
|
Nlm Unique ID: 101306166 Medline TA: J Diabetes Sci Technol Country: United States |
Other Details:
|
Languages: eng Pagination: 743-7 Citation Subset: IM |
Copyright Information:
|
Copyright 2009 Diabetes Technology Society. |
Affiliation:
|
US Air Force Medical Corps, Endocrinology Service, Lackland Air Force Base, Texas 78236, USA. mark.true@lackland.af.mil |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Biological Markers
/
blood* Deoxyglucose / blood Diabetes Mellitus / blood* Fructosamine / blood Hemoglobin A, Glycosylated / metabolism Humans Individualized Medicine* |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Hemoglobin A, Glycosylated; 0/hemoglobin A1c protein, human; 154-17-6/Deoxyglucose; 154-58-5/1,5-anhydroglucitol; 4429-04-3/Fructosamine |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Personalized medicine in diabetes: regulatory considerations.
Next Document: Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective...